基于决策树模型的强骨胶囊联合阿仑膦酸钠片治疗原发性骨质疏松症的药物经济学研究  

Pharmacoeconomic Study of Qianggu Capsules Combined with Alendronate Sodium Tablets in the Treatment of Primary Osteoporosis Based on Decision Tree Model

作　　者：崔鑫 韩晟[2] 李薇 孙春全 石丰豪 姜俊杰[1] 谢雁鸣[1] CUI Xin;HAN Sheng;LI Wei;SUN Chunquan;SHI Fenghao;JIANG Junjie;XIE Yanming(Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences,Beijing 100700,China;International Research Center for Medicinal Administration,Peking University,Beijing 100191,China;Dept.of Prevention and Treatment,Yuquan Hospital of Tsinghua University,Beijing 100049,China)

机构地区：[1]中国中医科学院中医临床基础医学研究所,北京100700 [2]北京大学医药管理国际研究中心,北京100191 [3]清华大学玉泉医院治未病科,北京100049

出　　处：《中国医院用药评价与分析》2023年第5期588-591,共4页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：国家重点研发计划项目(No.2018YFC1707400)。

摘　　要：目的:评价强骨胶囊(QC)治疗原发性骨质疏松症(POP)的经济性,以期为卫生医疗资源的合理配置提供参考依据。方法:采用TreeAge Pro软件,对QC+阿仑膦酸钠片(AST)对比单纯使用AST干预POP进行成本-效果分析,成本参数源自米内网数据库和相关文献;同时,根据一项临床研究得出的视觉模拟法(VAS)评分对两种治疗方案短期内的经济性进行评价,模型模拟的干预时间为6个月。通过单因素敏感性分析、概率敏感性分析对本研究结果的稳健性进行验证。结果:基础分析结果显示,QC+AST组治疗方案的增量成本-效果比为1982.69元/分,即相比于单纯使用AST,POP患者使用QC+AST每多降低1分VAS评分需多花费1982.69元;当患者的个人支付意愿阈值>1982.69元时,QC+AST组治疗方案具有经济性的概率高于AST组。敏感性分析结果验证了基础分析结果的稳健性,QC+AST组的临床疗效、药品单价和患者用药依从性对研究结果有一定影响,当患者的个人支付意愿阈值>1400元时,具有更高经济性概率的干预方案与基础分析结果一致。结论:当个人支付意愿阈值>1400元时,POP患者选用QC+AST治疗改善疼痛症状比单纯使用AST更具有经济性。OBJECTIVE:To evaluate the economy of Qianggu capsules(QC)in the treatment of primary osteoporosis(POP),so as to provide reference for the rational allocation of medical medication resources.METHODS:TreeAge Pro software was used to analyze the cost-effectiveness of QC+Alendronate sodium tablets(AST)vs.AST on POP.The cost parameters were obtained from the Menet database and related literature.Meanwhile,the short-term economic efficiency of two treatment was evaluated according to the decrease in visual analogue method(VAS)score obtained from the clinical study,and the intervention time simulated by the model was 6 months.The robustness of this study was verified by single factor sensitivity analysis and probabilistic sensitivity analysis.RESULTS:The results of basic analysis showed that the incremental cost-effectiveness ratio of QC+AST group was 1982.69 yuan/point,that is,compared with AST alone,the use of QC+AST for POP patients would cost 1982.69 yuan more for each additional 1 point of VAS score reduction.When the patients’personal willingness to pay threshold was higher than 1982.69 yuan,the probability of QC+AST group being economic was higher than that of AST group.The results of sensitivity analysis verified the robustness of the results of the basic analysis.The clinical efficacy,price of QC and medication compliance of the patient in QC+AST group had a certain impact on the results of the study.When the patients’personal willingness to pay threshold was more than 1400 yuan,the intervention regimen with higher economic probability was consistent with the results of the basic analysis.CONCLUSIONS:When the individual willing to pay threshold is more than 1400 yuan,it is more economical for POP patients to use QC+AST to improve pain symptoms than AST alone.

关 键 词：强骨胶囊 药物经济学评价 骨质疏松 成本-效果分析 阿仑膦酸钠片 

分 类 号：R932[医药卫生—生药学]